Grifols Q1 profit doubles on Talecris
MADRID, April 24
MADRID, April 24 (Reuters) - Grifols, the world's third largest blood products maker, said first quarter net profit doubled to 67.5 million euros ($88.6 million) from a year ago, lifted by contribution from U.S. peer Talecris.
The net profit figure includes financial costs from the $4 billion purchase of Talecris last year.
The Barcelona-based drug company said revenues also benefited from the merger, rising 17.7 percent to 666.7 million euros. ($1 = 0.7619 euros) (Reporting By Tracy Rucinski; Editing by Sonya Dowsett)